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Background: Metabolic tumour volume (MTV) obtained from pre-treatment 18 F-fluorodeoxydeglucose positron
emission tomography with computed tomography (PET-CT) has been validated as an independent predictive factor
of outcomes in head and neck cancer patients (HNC) treated with primary chemoradiotherapy (CRT). However its
role in patients treated with primary surgery has not yet been studied.
Objective: To evaluate the prognostic value of MTV in patients treated with primary surgery for oral cavity
squamous cell carcinoma (OCSCC).
Method: Demographic and survival data was obtained from patients diagnosed with OCSCC from 2008–2012 in
Alberta, Canada. All patients included in the study had PET-CT scan before curative surgical resection. MTV and
maximum standardized uptake value (SUVmax) value was delineated from pre-treatment PET-CT scans using Segami
Oasis software (Columbus, OH). MTV and SUVmax were divided into intertertile thirds before statistical analysis to
allow for in-group comparison of survival.
Results: A total of 80 patients were analyzed using SPSS ver. 20.0 (SPSS Inc, Chicago, IL). Five-year overall, and
disease-free survival using Kaplan-Meier curves were 70% and 73% respectively. When the combined SUVmax
(tumour primary and locoregional metastasis) was evaluated, it failed to predict overall (HR = 1.0, p = 0.99) or
disease-free survival (HR = 1.0, p = 0.227).
Conversely an increase in MTV of 17.5 mL (difference between the highest and lowest MTV tertile) was associated
with a 12.4 fold increase in risk of disease recurrence (p < 0.001) and an 11.2 fold increase in the risk of death
(p < 0.05).
Conclusions: This study shows that MTV is an independent adverse prognostic factor for death and disease
recurrence in OCSCC treated with primary surgery.
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Head and Neck cancer (HNC) accounts for 5% of all
malignancies worldwide with oral cavity squamous cell
carcinoma (OCSCC) being the most common site of oc-
currence [1,2]. Traditionally, successful treatment and
better prognosis often depended on tumour staging,
local extension, anatomical tumour site, histotype, lymph
node involvement and locoregional disease control [3-6].* Correspondence: dan.o'connell@albertahealthservices.ca
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unless otherwise stated.Recent developments in tumour and protein markers
have helped with better patient selection leading to im-
proved survival benefits [4,5]. 18 F-fluorodeoxydeglucose
positron emission tomography with computed tomog-
raphy (PET-CT) plays a major role in the management
of HNC patients owing largely to its ability to systemat-
ically measure tumour burden [7-10]. As a result it has
become the standard of care in many centers for staging,
evaluation of nodal and distant metastasis as well as key
roles in radiation planning [7,10,11]. Maximum stan-
dardized uptake value (SUVmax) delineated from pre-
treatment PET-CT has had mixed results in its role as aLtd. This is an Open Access article distributed under the terms of the Creative
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radiotherapy [4,12]. Metabolic tumour volume (MTV)
calculated as the product of the SUVmax and tumour vol-
ume has recently been validated as an independent pre-
dictive factor of outcomes in head and neck cancer
patients (HNC) treated with primary chemoradiotherapy
(CRT) [5]. Its role in OCSCC treated with primary surgi-
cal resection (S) with the addition of radiotherapy (S-RT)
and chemotherapy (S-CRT) has never been investigated.
The objective of this study was to assess the prognostic
value of MTV in patients treated with primary surgery for
OCSCC.
Method
Ethics approval was granted by the University of Alberta’s
Health Research Ethics Board (HREB) and the Alberta
Cancer Board.
Patients
Inclusion criteria were defined as:
1. Biopsy-proven OCSCC.
2. Treatment in Alberta with curative intent
3. Residents of Alberta > 18 years of age
4. PET-CT Scans prior to curative treatment
Exclusion criteria were defined as PET/CT
1. Previous HNC with or without treatment
2. Refusal of prescribed treatment
3. Treatment with palliative intent
4. Incomplete data sets from chart review
Data collection
All patients diagnosed with an OCSCC within the Capital
Health Zone in Alberta between January 1, 2008 and
January 1, 2012 were identified in the Alberta Cancer
Registry (ACR). The ACR, established in 1942, is a
population-based registry that records and maintains
data of all new cancer cases, their treatments, and
resulting deaths occurring in the province. The ACR is
operated by Alberta Health Services Cancer Care and
follows patients longitudinally and prospectively [13].
Demographic, survival and clincopathologic data were
extracted from the ACR database. A physical review of
outpatient, inpatient, and cancer clinic records was under-
taken to confirm data accuracy and extract relevant pa-
tient, tumour, treatment, follow-up, survival data, as well
as Eastern Cooperative Oncology Group (ECOG) per-
formance scores [14]. Charlson Comorbidity Index (CCI)
scores, which were not included in the ACR database,
were calculated using relevant comorbidities taken from
chart review [15]. Date of diagnosis was defined as the
date of pathologically confirmed OCSCC.Staging
Staging of the tumours was clinical and according to the
seventh edition of the American Joint Committee on
Cancer (AJCC) TNM staging manual [16].
Treatment
All patients underwent curative surgical resection consist-
ing of tumor ablation with variations of primary closure,
locoregional or free tissue transfer reconstruction, and
uni- or bilateral neck dissection. Patients receiving RT or
CRT for distant metastases or palliation were not in-
cluded. S-RT patients underwent surgical resection and
adjuvant RT within 6–8 weeks post-operatively. S-CRT
patients received surgical resection followed by adjuvant
CRT within 6–8 weeks of their operation. Single agent
cisplatin or carboplatin based CRT protocols were used
exclusively for all patients.
PET-CT imaging protocol
All patients were scanned using a Gemini TF 16-slice
PET-CT scanner system (Philips Healthcare, Andover, MA).
Patients were fasted a minimum of 4 hours before imaging
(typically from midnight the night before). 18F-fluorodeoxy-
glucose (FDG) was injected intravenously at a dose of
5.18 MBq/kg. A 60-minute uptake period was waited
prior to imaging.
PET imaging
With the patient in a supine position, PET scans were
acquired in two separate acquisitions. Initially a scan
was performed from the top of the shoulders to the
mid-thigh level with the arms elevated. Scan times of
1 minute per bed acquisition were used for patients
weighing less than 100 kg and 2 minutes for patients
with a weight of 100 kg or greater. A second PET scan
was performed from the mid brain level to the carina
with the arms down at an acquisition time of 2 minutes
per bed position.
CT imaging
After each PET images acquisition a corresponding CT
scan was performed for both anatomic assessment and
attenuation correction. This was typically performed
with the administration of IV contrast. After the initial
PET, 100 mL of intravenous contrast (Omnipaque 300,
GE Healthcare, Buckinghamshire, UK) was injected at
a rate of 3.5 mL/sec followed by 25 mL of saline at
3.0 mL/sec. A helical CT acquisition was obtained from
the top of the shoulders to the mid-thigh level using
dose modulation with a maximum 250 mAs, 120 kVp,
and a contrast delay of 28 seconds. After the second
PET acquisition a second IV contrast bolus of 40 mL at
1 mL/sec followed by 10 mL at 2.5 mL/sec followed by
25 mL saline at 2 mL/sec was administered. A second
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mid-brain to the carina using dose modulation with a
maximum 350 mAs, 120 kVp, and 50 second contrast
delay.
Image reconstruction
The PET images were reconstructed using vendor sup-
plied ASTONISH time-of-flight iterative reconstruction
with CT-based attenuation correction (Philips Healthcare,
Andover, MA). The CT images through the neck were re-
constructed for display with 1 mm slice thickness at 1 mm
intervals. The CT images through the chest, abdomen,
and pelvis were reconstructed for display with 3 mm slice
thickness at 1.5 mm intervals.
Measurement of tumour volume
All images were reviewed using Oasis workstation software
(Segami Corporation, Columbus, OH). The PET images,
CT images, and fused PET-CT images were reviewed in
transverse, sagittal, and coronal planes as show in Figure 1.
A spherical volumetric region of interest was placed around
the lesions of interest based on the evaluation of the PET
and CT datasets. Diagnostic nuclear medicine reports and
final radiation treatment planning volumes were used as
reference when identifying the lesions. This was performed
for the primary tumor and involved lymph nodes individu-
ally as well as the total group as a composite. MTV was de-
fined as the volume of hypermetabolic tissue within the
region of interest with a standardized uptake volume (SUV)
greater than or equal to 2.5. This threshold intensity value
has been identified and used in several previous studies
validating MTV as a predictive factor for HNC [4,5]. This
volume was automatically determined within the region of
interest by the review software. The average SUV and
SUVmax for the region with SUV greater than or equal to
2.5 was also determined.
Outcomes
The primary outcome was set as the prognostic utility of
MTV on overall survival. This was defined, as the time
from the date of diagnosis to the date of death or last
known date the patient was alive. Secondary outcome
was set as the prognostic utility of MTV on disease-free
survival, calculated as the time between the date of diag-
nosis to the date of OCSCC recurrence anywhere in the
body. Thus, if patients died without any evidence of dis-
ease, they were considered disease free at the time of
death.
Follow-up
All patients were followed at regional cancer treatment
centers at regular intervals following treatment. Dates of
follow-up, up to November 1, 2013 were recorded. Patients
who were suspected to have disease recurrence underwenta metastatic workup including appropriate imaging,
endoscopy and biopsy as per standardized institutional
guidelines.
Statistical analysis
Baseline characteristics were compared using standard
modes of comparison between multiple groups. Continu-
ous data was analyzed using analysis of variance (ANOVA),
with a Bonferoni correction factor for multiple compari-
sons. Categorical data was compared using the chi-squared
test. Overall, disease-specific and disease-free survival
rates were performed using Kaplan-Meier analyses to
determine estimated actuarial survival rates. PET-CT
endpoints (SUVmax and MTV) used for statistical ana-
lysis were the total MTV and SUVmax (value of the pri-
mary tumour in addition to any local region metastasis).
Associations between PET-CT endpoints and outcome
(disease-specific, disease-free, and overall survival) were
assessed with a Cox proportional hazard model for uni-
variate and multivariate predictions. Before entry into
the proportional hazard model, each PET-CT endpoint
was normalized to its intertertile ranges (difference be-
tween third and first tertile) to allow for in-group survival
comparisons. Covariates of age, gender, clinical T-stage
and N-Stage, ECOG performance status, and CCI scores
were used for the Cox-regression analysis. Level of signifi-
cance was set as p < 0.05. Analyses were performed with
SPSS Statistics 20.0 (SPSS Inc, Chicago, IL).
Results
One hundred and sixty-one patients were diagnosed with
OCSCC in the capital health zone of Alberta from 2008 to
2012. Eighty-one were excluded from the final analysis: 11
refused any form of treatment, 5 had therapy outside of
Alberta, 10 had palliative treatments, 45 patients did not
receive a pre-treatment PET-CT. Five had misclassified
tumour subsites, which were not in the oral cavity, and
5 had significantly incomplete data, precluding any data
analysis. A total of 80 patients were left for analysis.
Table 1 demonstrates patient demographic and tumour
variables. All patients included for analysis had undergone
a standard metastatic workup and all were staged M0 at
the time of diagnosis. The average age was found to be
62.1 (Range 30–87). The majority of the patient had
cancer of the tongue (43.0%) and almost all had locally
advanced OCSCC (15.0% Stage III and 53.8% Stage IV).
Mean CCI and ECOG scores were found to be 1.2
(Range 0–6) and 1.0 (Range 0–3) respectively.
Treatment analysis
Twenty-three (28.8%) patients received primary surgery
as their only treatment modality and 57 (71.2%) patients
had multi-modality treatment with the following classi-
fication: 37 (46.2%) had surgery followed by adjuvant
AB
C
Figure 1 Maximum intensity projection views of 18
F-fluorodeoxyglucose positron emission tomography scans
for a patient with Stage III oral cavity cancer with (A) axial
view, (B) coronal view, and (C) sagittal view.
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chemoradiotherapy (Table 1).
Survival analysis
The mean follow-up for all patients was 1.9 year
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Tongue 34 (43.0)























Abbreviations: no number, yrs years, cT-stage clinical T-stage, cN-stage clinical
N-stage, S surgery, S-RT surgery followed by adjuvant radiotherapy, S-CRT surgery
followed by adjuvant chemoradiotherapy.
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tients died from non-head and neck cancer-related
causes and 1 died of non-cancer related causes. Figure 2
demonstrates Kaplan-Meier for estimated overall and
disease-free survival for all patients. Five-year overall
and disease-free survival were found to be 70% and
73% respectively.Prognostic value
MTV was defined as the MTV of the primary tumour in
addition to any locoregional metastasis. The total MTV
predicted disease-free and overall survival. The median
total MTV was 7.4 cm3 (range, 2.1-72.1 cm3). Figure 3
shows overall and disease-free survival by tertiles of MTV.
An After accounting for age, gender, CCI score, ECOG,
T-stage, and N-stage, Cox-regression analysis showed
an increase in MTV of 17.5 mL (difference between the
first and third tertile) was associated with a 12.4 fold in-
crease in risk of disease recurrence (p < 0.001) and a
11.2 fold increase in the risk of death (p < 0.05). When
the combined SUVmax was evaluated, it failed to pre-
dict overall (HR = 1.0, p = 0.99) or disease-free survival
(HR = 1.0, p = 0.227).Discussion
HNC diagnosis and treatment have evolved greatly in re-
cent years [17-20]. The use of prognostic factors and
tumour biomarkers in the past decade has changed the
landscape of this debilitating disease [19,21]. Treatment
outcomes however remain heterogeneous in nature. Sub-
stantial efforts have been focused on studying the identifi-
cation of novel biologic parameters to further stratify risk
groups with the goal of individualized treatment strategies
for patients. PET-CT as an imaging modality has emerged
as the standard of care in recent years for HNC patients
aiding in staging, radiotherapy planning, and follow-up of
treatment responses [8,11]. The ability of PET-CT to sys-
tematically measure tumor burden may directly predict
locoregional control and survival as compared with previ-
ous identified clinical and pathological prognostic factors
including age, anatomic subsite, and co-morbidity scores.
MTV obtained from pre-treatment PET-CT as a variable
of SUVmax and tumour size has been previously reported
and validated to predict outcomes in HNC patients [4,5].
These results were only isolated to a group of patients
treated with primary CRT, with the MTV showing an abil-
ity to predict treatment response to patients undergoing
HNC treatments with CRT protocols. The impetus for
this study was to examine the prognostic utility of MTV
defined by ability to predict disease recurrence and disease
specific survival from pre-treatment PET-CT in oral cavity
squamous cell cancer (OCSCC) patients treated with pri-
mary surgery.In this study MTV was shown to be an independent
prognostic factor in a group of OCSCC patients treated
with primary surgery. Figure 2 demonstrates patient
overall and disease-free survival divided by tertiles. The
difference in MTV between the highest MTV tertile and
lowest was associated with a 12.4 fold increase in the
risk of disease recurrence and 11.2 fold increase in the
risk of death. This echoes the findings of La et al. who
published the original paper on MTV as a prognostic
factor HNC [4]. In their study, MTV was associated with
a 1.9 fold increase in disease recurrence and 2.0 increase
in the risk of death. The difference in results of our
studies could certainly be attributed to our patient char-
acteristics as well as our treatment modalities. Previously
studies looking at MTV had a heterogeneous population
consisting of multiple HNC subsites while our popula-
tion was strictly OCSCC where the majority of patients
had Stage IV disease. In addition, 25% of our patient
population required triple modality treatment owing to
the advanced nature of their disease. It is has been previ-
ously shown that S-CRT offers greater survival advan-
tage given certain high-risk features on pathology as well
as advanced tumour profiles [22,23]. Extracapsular spread,
perineural invasion, as well as lymphovascular invasion
could have certainly attributed to the results. These fea-
tures were not studied independently, however as to their
relationship with MTV in our study and remains to be ex-
plicated from further research.
AJCC TNM cancer staging system is used to classify
tumours based on tumour dimensions as well as the
presence of nodal disease. Traditionally, this staging sys-
tem has been the standard of care in predicting outcomes
in HNC. This cancer staging system, while addresses
tumor variability does not account for gross tumour
volume (GTV) [24]. Because many malignant lesions
can be irregularly shaped or sized, this one-dimensional
determinant is likely to fail to capture the information
that a 3D approach can provide. GTV has been previ-
ously validated as a independent predictive factor for
HNC outcomes [9]. The utility of GTV compared to the
TNM staging system as a better predictor of survival
outcomes remains to be elucidated after numerous
studies [24,25]. In our study, T and N-staging was incor-
porated as part of a cox-regression analysis proving that
MTV was an independent prognostic factor of OCSCC
outcomes. However, it’s prognostic value in comparison
to that of the TNM staging system was beyond the
scope of the study. Further research looking into MTV
versus that of the traditional tumor staging system
could yield interesting results in the new era of radio-
logic imaging systems.
SUVmax is the most studied PET-CT metric for HNC.
Predictive utility for SUVmax was initially promising
however have been difficult to reproduce [12,26]. Moeller,
AB
Figure 2 Kaplan-Meier plots of (A) Overall survival, and (B) Disease-free survival rates for patients with oral cavity tumours.
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AB
Figure 3 Kaplan-Meier plots by Tertiles of Metabolic Tumour Volume (A) Overall survival, and (B) Disease-free survival rates for patients
with oral cavity tumours. Abbreviations: MTV, metabolic tumour volume.
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was not able to show its reproducibility and validity
as a prognostic factor for HNC treatments [27]. This
lack of reproducibility was shown within several
other studies looking at MTV and SUVmax utility as
well. No study has previously looked at the relation-
ship of SUVmax and primarily surgically treated HNC
patients. While not the main focus of this study,
SUVmax was not found to be a statistically significant
prognostic biomarker for an OCSCC patient population
treated with primary surgery. Certainly, further studies in-
volving a prospective design could be utilized to help fur-
ther clarify this relationship.
Limitations of this study are acknowledged. The
population-based single institution design of the study
precluded any controls. However, factors such as age,
gender, T and N-stage, treatment modality, CCI as well
as ECOG performance scores that could have been
possible confounding effects were accounted for in a
robust cox regression analysis. Our institution used a
standardized protocol with PET imaging and a single
software system for image analysis. Different imaging
protocols, PET scanners, and imaging processing tech-
niques would potentially affect the results and have an
impact on the effectiveness of MTV. Given these limi-
tations, a validation prospective multi-institutional
study could be the next step in eliciting the relation-
ship between MTV and survival in a primary surgically
treated patient population.
The results of this study demonstrate utility of MTV
as an independent and robust prognostic marker that is
easily obtainable from pre-treatment PET-CT imaging in
an OCSCC population treated with primary surgery.
Overall survival as well as disease-free survival was both
found be predictable by MTV. Previous studies that in-
cluded patients treated with CRT have demonstrated its
value in predicting outcomes. This is the first study, to
our knowledge to report the use of MTV in patients
with head and neck cancer treated surgically. Our find-
ings suggest that MTV is not only a predictive factor for
CRT treatments in HNC patients, but also an independ-
ent prognostic factor of overall and disease-free survival
to patients with OCSCC. It is possible that MTV can be
used in similar patient populations to provide guidance
on types of adjuvant therapies for OCSCC.
Conclusion
This population based cohort study demonstrates that
pre-treatment MTV delineated from PET-CT is an in-
dependent and robust prognostic marker for OCSCC
treated with primary surgery. Patients with higher
MTV values should be further evaluated for the possi-
bility of using escalated treatments regimens in their
OCSCC treatment.Ethics approval
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